Smith & Nephew (LON:SN) Stock Price Target Lowered at Jefferies Financial Group

Smith & Nephew (LON:SN) had its target price reduced by equities research analysts at Jefferies Financial Group from GBX 1,500 to GBX 1,400 in a research note issued on Thursday, London Stock Exchange reports. The brokerage presently has a “buy” rating on the stock. Jefferies Financial Group‘s target price indicates a potential upside of 17.65% from the company’s previous close.

Other equities research analysts have also recently issued reports about the company. Citigroup cut Smith & Nephew to a “buy” rating in a research note on Friday, July 10th. JPMorgan Chase & Co. reduced their target price on shares of Smith & Nephew from GBX 1,438 to GBX 1,290 and set a “neutral” rating for the company in a report on Thursday, August 6th. Berenberg Bank decreased their price target on shares of Smith & Nephew from GBX 1,300 to GBX 1,250 and set a “hold” rating for the company in a research report on Friday, August 14th. Deutsche Bank Aktiengesellschaft restated a “hold” rating and issued a GBX 1,250 price target on shares of Smith & Nephew in a report on Tuesday, September 15th. Finally, Shore Capital Group reaffirmed a “buy” rating and issued a GBX 1,000 price objective on shares of Smith & Nephew in a research report on Tuesday, July 21st. Three analysts have rated the stock with a Buy rating and six have issued a Hold rating to the company’s stock. Based on data from MarketBeat, Smith & Nephew has a consensus rating of “Hold” and a consensus target price of GBX 1,242.50.

Smith & Nephew Stock Performance

Smith & Nephew stock opened at GBX 1,190 on Thursday. The company has a quick ratio of 0.84, a current ratio of 2.14 and a debt-to-equity ratio of 73.07. The company has a market capitalization of £13.05 billion, a P/E ratio of 42.84, a PEG ratio of 0.46 and a beta of 0.69. The company’s fifty day moving average is GBX 1,053.81 and its 200 day moving average is GBX 1,152.03.

About Smith & Nephew

Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and services in the United Kingdom and internationally. It operates through three segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. The company offers knee implant products for knee replacement procedures; hip implants for revision procedures; trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures; and other reconstruction products.